Prospective single arm, single center observational study to evaluate Quality of Life (Qol) after stereotactic body radiotherapy for patients with hepatocellular cancer. Patients will receive work-up, treatment and follow-up exclusively as routinely done except additional quality of life measurements. Qol will be measured by standardized and validated EORTC questionaires at different time points during routine follow-up.
histologically or radiologically proven hepatocellular carcinoma
1-3 lesions suitable for stereotactic radiation therapy
indication for SBRT according to multidisciplinary board evaluation
age >= 18 years
age < 18 years
prior HCC specific systemic therapy
concurrent oncological systemic treatment
distant metastases
adult patients receiving routine SBRT to 1-3 intrahepatic HCC lesions
Cohort
Prospective
observational
Other interventionnone (observational study)
Quality of life
Quality of life
acute toxicity
physician-related acute toxicity
late toxicity
physician-related late toxicity
response
response to treatment according to imaging
local control
absence of regrowth inside the treated lesion
Click on the lead sponsor to view all of their trials.
